Tag Archives: (AMGN)

The Dividend King That Keeps Growing It’s Kingdom

A Chicago lawyer named Russ Gremel walked into a brokerage in 1945 with $1,000 and a theory so simple it barely qualified as an investment thesis. He figured people would always need medicine and women would always buy makeup, so he bought shares in Walgreens (WBA) and promptly forgot about them. Seventy years later, when […]

Why Isn’t Anyone Watching This Biotech Do Everything Right?

Here’s a test of whether your analyst does actual homework or just regurgitates press releases: ask them about Regeneron’s (REGN) development balance with Sanofi (SNY). I can almost guarantee the blank stares that usually follow. That obscure line item buried in the 10-Q filing dropped $253 million last quarter to $1.2 billion, which means Regeneron’s […]

Why This Biotech Owns The Aging Population Trade

Walking through the oncology ward at Cedars-Sinai last week, I noticed something interesting. The pharmacy techs were wheeling around more Amgen (AMGN) products than I’d seen in months. Repatha for cholesterol management, EVENITY for osteoporosis, and their expanding biosimilars portfolio. It got me thinking about why Wall Street keeps sleeping on this biotech behemoth. It’s […]

Blink And You Miss It

Did you know that the average person blinks about 17,000 times a day? Well, if you blinked during the American Diabetes Association conference, you might have missed Eli Lilly (LLY) delivering some of the most impressive clinical data I’ve seen in years. While their competitors stumbled through disappointing presentations, Lilly quietly demonstrated why they’re positioning […]

The Market Outlook for the Week Ahead, or The Case of the Missing Tariffs

NOTE: This is a Jeffrey Epstein-free letter. The Volatility Index ($VIX) closed on Friday at a lowly $16.45. At that price, the index is predicting that the S&P 500 will move up or down less than 1.05% over the next 30 days. Somehow, I don’t think that is going to happen, especially going into September, […]